| Name | cytosolic phospholipase A2 |
|---|---|
| Synonyms | CPLA 2; CPLA2; CPLA2 alpha; Cytosolic phospholipase A2; Lysophospholipase; PLA2G4A; Phospholipase A2… |
| Name | cycloheximide |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 15522829 | Anfuso CD, Assero G, Lupo G, Nicotra A, Cannavo G, Strosznajder RP, Rapisarda P, Pluta R, Alberghina M: Amyloid beta (1-42) and its beta (25-35) fragment induce activation and membrane translocation of cytosolic phospholipase A2 in bovine retina capillary pericytes. Biochim Biophys Acta. 2004 Nov 8;1686(1-2):125-38. Treatment with inhibitors (AACOCF (3), staurosporine and cycloheximide) resulted in a sharp decrease in basal and stimulated cPLA (2) activity. |
36(0,1,1,6) | Details |
| 18708082 | Luo SF, Lin CC, Chen HC, Lin WN, Lee IT, Lee CW, Hsiao LD, Yang CM: Involvement of MAPKs, NF-kappaB and p300 co-activator in IL-1beta-induced cytosolic phospholipase A2 expression in canine tracheal smooth muscle cells. Toxicol Appl Pharmacol. 2008 Nov 1;232(3):396-407. Epub 2008 Jul 29. IL-1beta-induced cPLA2 expression and production was inhibited by actinomycin D and cycloheximide, indicating the involvement of transcriptional and translational events in these responses. |
2(0,0,0,2) | Details |
| 15588231 | Merkel O, Oskolkova OV, Raab F, El-Toukhy R, Paltauf F: Regulation of activity in vitro and in vivo of three phospholipases B from Saccharomyces cerevisiae. Biochem J. 2005 Apr 15;387(Pt 2):489-96. In vivo, cycloheximide strongly inhibits the breakdown of PtdIns, and to a lesser extent PtdCho. The genome of the yeast, Saccharomyces cerevisiae, contains three highly similar genes coding for phospholipases B/lysophospholipases. |
1(0,0,0,1) | Details |
| 16464966 | Balzary RW, Cocks TM: Lipopolysaccharide induces epithelium- and (2)-dependent relaxation of mouse isolated trachea through activation of cyclooxygenase (COX)-1 and COX-2. J Pharmacol Exp Ther. 2006 May;317(2):806-12. Epub 2006 Feb 7. The LPS antagonist polymixin B; the nonselective COX inhibitor indomethacin; the selective COX-1 and COX-2 inhibitors 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole (SC560) and 4-[5-(4-chlorophenyl)-1-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonam ide (SC236), respectively; the transcription inhibitor actinomycin D; the translation inhibitor cycloheximide; the p38 mitogen-activated protein kinase (p38 MAPK) inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imadazole (SB203580); and a combination of the mixed DP/EP1/EP2 receptor antagonist 6-isopropoxy-9-xanthone-2-carboxylic acid (AH6809) and the EP4 receptor antagonist 4'-[3-butyl-5-oxo-1-(2-trifluoromethyl-phenyl)-1-5-dihydro-[1,2,4] triazol- 4-ylmethyl]-biphenyl-2- (3-methyl-thiophene-2-carbonyl)-amide (L-161982) all abolished relaxation to LPS, giving instead slowly developing, small contractions over 60 min. Activation of both COX-1 and COX-2 seems to be essential for this novel response to LPS, which also involves cPLA (2), p38 MAPK, NF-kappaB, and an unidentified NF-kappaB-independent, labile regulatory protein. |
1(0,0,0,1) | Details |